Oritavancin diphosphate is primarily used as an antibiotic for treating acute bacterial skin and skin structure infections caused by susceptible Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). It is administered intravenously and works by inhibiting cell wall synthesis, leading to bacterial cell death. Its long half-life allows for a single-dose treatment regimen, improving patient compliance and reducing healthcare visits. This makes it particularly useful in outpatient settings or for patients requiring simplified treatment schedules. Additionally, it is effective against complex infections where other antibiotics may fail, offering a reliable option for managing severe or resistant bacterial infections.